| Through new drug launches, panel discussions, and similar forums. | 환자 권익 옹호
> 약물 및 관련 치료 | 규제 파트너십
> 규제 기관과의 협력 | 1,000 | Regional | Sometimes | 115028447628 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | 암
> 암: 대부분의 유형 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 10,000 | National | Regularly | 114998266569 |
| We assess cost-effectiveness. | 간
> 간 질환: 대부분의 유형 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Sometimes | 114998327089 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | 일반 건강
> 의료 서비스 제공 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Regularly | 115009387424 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | 암
> 암: 대부분의 유형 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 10,000 | National | Regularly | 114998266569 |
| Attendance at relevant committee meetings and informal consultative sessions. | 선천성
> 선천성: 심장 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 10,000 | National | Rarely | 115003445044 |
| Activities include policy forums, stakeholder consultations, meetings with relevant government ministries, and related engagements. | 희귀
> 희귀 질환: 대부분의 유형 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 1,000 | National | Regularly | 115033450975 |
| Convening public hearings in the National Assembly and submitting formal recommendations to the Ministry of Health and Welfare [in Korea]. | 정신 건강
> 정신 건강: 대부분의 상태 | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | 5,000 | Regional | Sometimes | 115019561629 |
| Activities included participation in policy forums advocating for the reimbursement of treatments currently excluded from public health insurance coverage, including Durvalumab and the graft-versus-host disease treatment Belumosudil. | 암
> 암: 혈액 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | 100,000 | Regional | Sometimes | 115008918207 |
| Convening of National Assembly public hearings. | 정신 건강
> 정신 건강: 대부분의 상태 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | 5,000 | Regional | Sometimes | 115019561629 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | 암
> 암: 혈액 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | 1,000 | Regional | Sometimes | 115028455157 |
| Activities include participation in forums and debates, submission of petitions to the 인권위 [국가인권위원회 – National Human Rights Commission]. | 환자 권익 옹호
> 환자 권리 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | 5,000 | Regional | Regularly | 115033350867 |
| Participated in a National Assembly policy forum on medicines not covered by public health insurance to convey the patient perspective. | 암
> 암: 유방 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | 5,000 | National | Sometimes | 115058944486 |
| A request for the re-listing of a Parkinson's disease treatment. | 신경퇴행성
> 파킨슨병 | 정책 및 법률에 영향 미치기
> 의료 서비스의 장벽/이상 현상 해결 | 5,000 | National | Rarely | 115055431165 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | 암
> 암: 대부분의 유형 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 10,000 | National | Regularly | 114998266569 |
| Participated in a National Assembly policy debate on non-reimbursable drugs to convey patients' voices, and engaged in a petition drive to advocate for reimbursement coverage. | 암
> 암: 유방 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 5,000 | National | Sometimes | 115058944486 |
| We assess cost-effectiveness. | 간
> 간 질환: 대부분의 유형 | 가격 책정 및 affordability 옹호
> 가격 검토 위원회 협상에 참여 | 100,000 | National | Sometimes | 114998327089 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | 암
> 암: 혈액 | 가격 책정 및 affordability 옹호
> 가격 검토 위원회 협상에 참여 | 1,000 | Regional | Sometimes | 115028455157 |
| Reimbursement rates for basic welfare recipients. | 정신 건강
> 정신 건강: 대부분의 상태 | 가격 책정 및 affordability 옹호
> 저소득층 및 취약계층의 비용 장벽 해소 | 5,000 | Regional | Sometimes | 115021952415 |
| Inclusion of medical devices — such as continuous glucose monitors and insulin pumps — on the national health insurance formulary. | 내분비
> 당뇨병: 1형 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 100,000 | National | No | 114998267322 |
| Activities included participation in policy forums advocating for the reimbursement of treatments currently excluded from public health insurance coverage, including Durvalumab [help the body's immune system recognize and destroy cancer] and the graft-versus-host disease treatment Belumosudil. | 암
> 암: 혈액 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 100,000 | Regional | Sometimes | 115008918207 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | 암
> 암: 혈액 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 1,000 | Regional | Sometimes | 115028455157 |
| Participated in a National Assembly policy debate on non-reimbursable drugs to convey patients' voices, and engaged in a petition drive to advocate for reimbursement coverage. | 암
> 암: 유방 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 5,000 | National | Sometimes | 115058944486 |
| A request for the re-listing of a Parkinson's disease treatment. | 신경퇴행성
> 파킨슨병 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 5,000 | National | Rarely | 115055431165 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | 일반 건강
> 의료 서비스 제공 | 근거 기반 환자 의견
> 환자 인사이트를 활용하여 의사 결정에 반영하세요 | 100,000 | National | Regularly | 115009387424 |
| We submit written recommendations on a regular basis. | 암
> 암: 혈액 | 근거 기반 환자 의견
> 환자 인사이트를 활용하여 의사 결정에 반영하세요 | 10,000 | National | Regularly | 115056090120 |
| Participated in a National Assembly policy forum on medicines not covered by public health insurance to convey the patient perspective. | 암
> 암: 유방 | 근거 기반 환자 의견
> 환자 인사이트를 활용하여 의사 결정에 반영하세요 | 5,000 | National | Sometimes | 115058944486 |
| We submit written recommendations on a regular basis. | 암
> 암: 혈액 | 근거 기반 환자 의견
> 증거와 인사이트를 정책 입력으로 전환 | 10,000 | National | Regularly | 115056090120 |
| Attendance at relevant committee meetings and informal consultative sessions. | 선천성
> 선천성: 심장 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 10,000 | National | Rarely | 115003445044 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | 일반 건강
> 의료 서비스 제공 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 100,000 | National | Regularly | 115009387424 |
| Activities include participation in forums and debates, submission of petitions to the 인권위 [국가인권위원회 – National Human Rights Commission]. | 환자 권익 옹호
> 환자 권리 | 환자 권리 보호/삶의 질 향상
> 환자 경험 보호/개선 | 5,000 | Regional | Regularly | 115033350867 |
상호작용
활동 및 옹호
7 멘션
